Oncology for the Inquisitive Mind

In our final ESMO 2024 analysis this week, we bring back Dr. Adam Brufsky, "a giant among men (and women)" in breast cancer research and management. He discusses the field, the pivotal updates in ESMO, and what this means for patients. He also explores many of the unanswered questions.Links to studies discussed in this episode (subscription may be required):DESTINYBREAST012KEYNOTE522Many other pearls of wisdom - so tune in!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Lung cancer treatment has changed seismically since 2018 and the NEJM publication of Keynote 189. This week, we have Dr. Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T; crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LAURA trial mention (osimertinib after definitive chemoradiotherapy)Links to studies discussed in this episode (subscription may be required):Checkmate77TADRIATICLAURASpecial mentionsFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

ESMO 2024 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings their greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best thing - Prof Anthony Joshua from St Vincent's Health and The Garvan Institute of Medical Research. This week, he discusses all things genitourinary cancer and gives a knockout performance.Enough boxing analogies - on with the show!Links to studies discussed in this episode (subscription may be required):PATCH+STAMPEDEARANOTESTAMPEDE (metformin Arm)PEACE-3SPLASHNIAGARAAMBASSADORTiNivo-2For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

With ESMO 24 firmly in the rearview mirror, the dust settling, and the end of the year closing in, Michael and Josh take one final look at the trials that may change practice, direct research, or are just generally interesting. This week, we interviewed Dr Geoffrey Chong, a medical oncologist specialising in gastrointestinal cancers who currently holds appointments at the Olivia Newton-John Cancer Wellness and Research Centre and the Northern Hospital.Enjoy!Links to studies discussed in this episode (subscription may be required):APOLLOLEAP-012CABINETINTERAACT-2MOONLIGHTNICHE-2NICHE-3TOPGEARRAMTASSOLARISFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

The end of the road approaches, and ESMO 2024 will soon be in the rearview mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO.Studies discussed in this episode:Biomarker analysis of PEACE-1ARANOTESTAMPEDE - Addition of MetforminClinical activity of BMS-986365, dual androgen receptor ligand-directed degrader and antagonist in heavily pretreated mCRPCNivo (3mg/kg) + ipi (1mg/kg) in molecularly-selected patients with mCRPCNeoadjuvant nivo/rela or nivo/ipi in TNBC with high TILsAdjuvant ribo + NSAI in patients with HR+/HER2- EBC: 4 year NATALEECabozantinib vs placebo for advanced NET after progression on prior therapy (CABINET)Osimertinib after definitive CRT: analysis of CNS and distant progression from LAURAPOTENTIALFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy.They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma.Links to studies discussed in this episode (subscription may be required):DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC)EV-302 - nectin four expressionUpFrontPSMA StudySplash Study (Lu-PNT2002)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.SplashDisitimab Vedotin

Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen to the boys' best bits from Barcelona on Day 2 of ESMO.Studies discussed in this episode:Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II studyA multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trialPathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based studyInterim analysis of GALAXIES Lung-201: belrestotug + dostarlimab in 1L for PD-L1 TPS >/= 50% NSCLCIvonescimab +/- ligufalimab + FOLFOXIRI as 1L treatment for mCRCEfficacy and safety of ribociclib + NSAI in younger patients with HR+/HER2- EBC (NATALEE)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and heartbreaks along with some important updates in the science and art of medical oncology.Michael and Josh cover a range of tumour types on day one, a slight deviation from our regular coverage. They look at hepatocellular carcinoma, renal cancers, and breast cancer, an eclectic but exciting mix of cancer types.Michael investigates HCC treatment with iparomlimab and tuvonaralimab with bevacizumab in a first line setting, along with some updated efficacy from the IMbrave050 trial. He finishes off his whirlwind tour of day one summarising some interesting education points in the metastatic colorectal cancer space. Josh looks at Tivozanib-Nivolumab in advanced RCC following immunotherapy, along with another trial where Belzutifan may be another treatment option. He finishes up with HER3-directed therapy!Links to studies discussed in this episode (subscription may be required):Phs II/III DUBHE-H-308Imbrave050 (HCC)TiNivo-2 Study (mRCC)Litespark 005 (mRCC)Checkmate 8HW (mCRC)Icarus-Breast 01 (mBreast Cancer)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.